Romiplostim, eltrombopag, and the recently FDA-licensed avatrombopag are TPO-RA that increase platelet counts in ITP by activating the c-mpl receptor, promoting the survival, proliferation, and differentiation of megakaryocytes and subsequently stimulating platelet production. Here, TPO is linked to autoimmune thrombocytopenic purpura.